Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients.
about
Induction of SOCS3 by liver X receptor suppresses the proliferation of hepatocellular carcinoma cellsCan Kushen injection combined with TACE improve therapeutic efficacy and safety in patients with advanced HCC? a systematic review and network meta-analysis.What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? a systematic review and network meta-analysis.Prognostic role of ABO blood group in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization.
P2860
Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մարտին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Tumor SOCS3 methylation status ...... and prognosis in HCC patients.
@ast
Tumor SOCS3 methylation status ...... and prognosis in HCC patients.
@en
type
label
Tumor SOCS3 methylation status ...... and prognosis in HCC patients.
@ast
Tumor SOCS3 methylation status ...... and prognosis in HCC patients.
@en
prefLabel
Tumor SOCS3 methylation status ...... and prognosis in HCC patients.
@ast
Tumor SOCS3 methylation status ...... and prognosis in HCC patients.
@en
P2093
P2860
P356
P1433
P1476
Tumor SOCS3 methylation status ...... and prognosis in HCC patients.
@en
P2093
Bei-Ge Jiang
Jian Huang
Liang-Liang Sun
Wei-Ping Zhou
P2860
P304
28621-28627
P356
10.18632/ONCOTARGET.16157
P407
P577
2017-03-13T00:00:00Z